Dirlotapide,a U.S. Food and Drug Administration-Approved First-in-Class Obesity Drug for Dogs—Will Humans Be Next?

Slentrol package insert. NADA #141–260. 820 600 000; October, 2006. Pfizer Animal Health, Div. Pfizer Inc., New York, New York 10017.

Lund EM Armstrong PJ Kirk CA Kolar LM Klausner JS. Health status and population characteristics of dogs and cats examined at private veterinary practices in the United States. J Am Vet Med Assoc. 1999 May 1; 214 (9): 1336–41.

McGreevy PD Thomson PC Pride C Fawcett A Grassi T Jones B. Prevalence of obesity in dogs examined by Australian veterinary practices and the risk factors involved. Vet Rec. 2005 May 28; 156 (22): 695–702.

Ogden CL Carroll MD Curtin LR McDowell MA Tabak CJ Flegal KM. Prevalence of overweight and obesity in the United States, 1999–2004. JAMA. 2006 Apr 5; 295 (13): 1549–55.

Li C Ford ES McGuire LC Mokdad AH. Increasing trends in waist circumference and abdominal obesity among US adults. Obesity (Silver Spring). 2007 Jan; 15 (1): 216–24.

Chandler CE Wilder DE Pettini JL Savoy YE Petras SF Chang G Vincent J Harwood HJ. CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans. J Lipid Res. 2003 Oct; 44 (10): 1887–901.

Ueshima K Akihisa-Umeno H Nagayoshi A Takakura S Matsuo M Mutoh S. Implitapide, a microsomal triglyceride transfer protein inhibitor, reduces progression of atherosclerosis in apolipoprotein E knockout mice fed a Western-type diet: involvement of the inhibition of postprandial triglyceride elevation. Biol Pharm Bull. 2005 Feb; 28 (2): 247–52.

Rader DJ Brewer HB Jr. Abetalipoproteinemia. New insights into lipoprotein assembly and vitamin E metabolism from a rare genetic disease. JAMA. 1993 Aug 18; 270 (7): 865–9.

Cuchel M Bloedon LT Szapary PO Kolansky DM Wolfe ML Sarkis A Millar JS Ikewaki K Siegelman ES Gregg RE Rader DJ. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med. 2007 Jan 11; 356 (2): 148–56.

Padwal RS Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet. 2007 Jan 6; 369 (9555): 71–7.

Krcik JA. Performance-enhancing substances: what athletes are using. Cleve Clin J Med. 2001 Apr; 68 (4): 283, 288–9, 295–7 passim.

Burnett JR Watts GF. MTP inhibition as a treatment for dyslipidaemias: time to deliver or empty promises? Expert Opin Ther Targets. 2007 Feb; 11 (2): 181–9.